The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection

Study Overview
=================
Brief Summary
-----------------
Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.

Conditions
-----------------
Uterine Cancer

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine group
* Drug: Control group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ patient scheduled for uterine cancer surgery Exclusion Criteria: ASA physical status Ⅳ severe hepatorenal disease infection metastasis to other organ problem with communication

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dexmedetomidine Group<br>dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery | Drug: Dexmedetomidine group<br>* dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery<br>|
| Placebo Comparator: Control Group<br>0.9% saline infusion | Drug: Control group<br>* 0.9% saline infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| natural killer cell cytotoxicity | Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea). | 1 minute before surgery | 
| natural killer cell cytotoxicity | Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea). | postoperative day 1 | 
| natural killer cell cytotoxicity | Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea). | postoperative day 3 | 
| natural killer cell cytotoxicity | Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea). | postoperative day 5 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inflammatory response | inflammatory response is assessed by measuring levels of proinflammatory cytokines. | 1 minute before surgery | 
| inflammatory response | inflammatory response is assessed by measuring levels of proinflammatory cytokines. | postoperative day 1 | 
| inflammatory response | inflammatory response is assessed by measuring levels of proinflammatory cytokines. | postoperative day 3 | 
| inflammatory response | inflammatory response is assessed by measuring levels of proinflammatory cytokines. | postoperative day 5 |